Epoxyeicosatrienoic acids (EETs) are potent vasodilators produced from arachidonic acid by cytochrome P450 (CYP) epoxygenases (EPOXs) and metabolized to vicinal diols by soluble epoxide hydrolase (sEH). In brain, EETs are produced by astrocytes and vascular endothelium and are involved in the control of cerebral blood flow (CBF). Recent evidence, however, suggests that EPOX and sEH are present in perivascular vasodilator nerve fibers innervating the cerebral surface vasculature. Herein we tested the hypothesis that EETs are a nervederived relaxing factor in the cerebral circulation. We first traced these fibers by retrograde labeling in the rat to the trigeminal (TG) and sphenopalatine ganglia (SPG). We then examined expression of CYP EPOXs and sEH in these ganglia. RT-PCR and western blot identified 
Introduction
Epoxyeicosatrienoic acids (EETs) are potent vasodilators and important regulators of vascular function that are synthesized from arachidonic acid by cytochrome P450 (CYP) epoxygenase (EPOX) enzymes of the CYP2C and CYP2J families (10, 24, 33) . The enzyme soluble epoxide hydrolase (sEH) is the dominant route of EETs degradation, catalyzing their metabolism to dihydroxyeicosatrienoic acids (DHETs) (9) . In the brain, EETs are known to be released from astrocytes and vascular endothelium (3, 18) . They directly dilate cerebral arteries (4, 8) and exert regulatory control over several facets of vascular function, including angiogenesis (19, 34) and platelet adhesion (14) . EETs are key regulators of cerebral blood flow (CBF), mediating neurovascular coupling in the intact brain (2, 20, 21) . Finally, EETs play an important role in the blood flow response to cerebral ischemia. Inhibition of sEH results in a reduction of ischemic damage in a mouse model of experimental stroke and is associated with elevated cortical blood flow during vascular occlusion (35, 36) .
Our group recently reported the presence of sEH-immunoreactivity (IR) in perivascular nerve fibers innervating the cortical surface vasculature including the middle cerebral (MCA) and basilar arteries (16) . This 'extrinsic' perivascular innervation of the cerebral vasculature includes two populations of vasodilator nerves: parasympathetic fibers originating in the sphenopalatine (SPG) and otic ganglia and sensory afferents that project to the trigeminal ganglia (TG) (13) .
Immunofluorescence double-labeling revealed that sEH-IR co-localized with markers for both the parasympathetic and sensory vasodilator fibers (16) . Despite the presence of sEH in these nerves, it remains unclear whether EETs contribute to the vasomotor actions of these perivascular fibers.
In the present study, we proposed that neuron-derived EETs are involved in the regulation of CBF by these perivascular vasodilator fibers. To test this novel neurogenic hypothesis, we traced these perivascular nerve fibers to their source ganglia, identifying the expression of specific CYP EPOX isoforms and sEH within these neuronal populations. The functional involvement of nerve-derived EETs in the control of CBF was then examined with in vivo models of neurogenic cerebrovasodilation, including electrical stimulation of the efferent cerebral perivascular vasodilator nerve supply as well as by chemical stimulation of sensory trigeminal fibers.
Materials and Methods
The present experiments were conducted in accordance with the National Institutes of Health guidelines for the care and use of animals in research under protocols approved by the Institutional Animal Care and Use Committee of Oregon Health and Science University.
Characterization of CYP epoxygenase and sEH expression in the TG and SPG
To determine the specific CYP EPOX isoforms expressed in the TG and SPG, an RT-PCR screen was conducted against 8 known rat EPOX isoforms from the CYP2C and CYP2J families (24) , in addition to sEH, using whole tissue from the TG and SPG. Four male 250-300g
Wistar rats (Charles River) were deeply anesthetized with 5% isofluorane and trans-cardially perfused with cold heparinized saline (1 U/ml). Bi-lateral TG and SPG were dissected and total tissue RNA was extracted per manufacturer's guidelines using an RNAqueous®-4PCR kit (Ambion). Whole tissue Poly-A RNA was reverse transcribed according to manufacturer's protocol with a RETROscript® reverse transcription kit (Ambion) using Oligo(dT) primers. PCR (30 cycles with 59°C annealing temperature) was conducted using a GeneAmp® PCR System 9700 (Applied Biosystems) with primers designed using online primer design software (Integrated DNA Technologies), the specificity of the sequences being confirmed by BLAST search. PCR products were run on a 2% agarose gel and visualized with 0.5 µg/ml ethidium bromide read on a Typhoon® Trio multi-modal scanner (Amersham). For each transcript, replicate PCR reactions were conducted from two separate animals (n = 2 biological replicates).
Negative controls included the omission of PCR template material and whole cell (no reverse transcriptase) RNA in the place of cDNA. Positive controls included PCR upon liver cDNA, in which EPOX isoforms and sEH are known to be abundantly expressed.
The expression of CYP2J and sEH proteins in the TG and SPG was confirmed by Western blot.
TG, SPG and liver tissue were dissected from 2 saline-perfused rats and mechanically dissociated. Crude cellular extracts (microsomal and cytosolic fractions, 30 µg) were electrophoresed at 200 V for 105 min on SDS-10% polyacrylaminde gels, then transferred to PVDF membranes for 120 min at 40 V. Membranes were washed 5% bovine serum albumin (BSA) for 1 hr at room temperature then immunoblotted with a rabbit polyclonal antibody raised against the peptide sequence FNPDHFLENGQFKKRE from human CYP2J2 (anti-CYP2J2pep4, 1:1000), which cross-reacts with both rat CYP2J isoforms, CYP2J3 and CYP2J4. Membranes were also blotted with rabbit anti-sEH (Santa Cruz, 1:500) polyclonal antibody. Secondary detection was conducted with Cy5-conjugated goat anti-rabbit secondary antibodies (Amersham) for 1 hr at room temperature. Membranes were imaged with a Typhoon® TRIO polymodal scanner (Amersham). Replicate blots (n = 3) were conducted on samples from 2 animals.
The cell type-specific expression of CYP2J and sEH proteins was determined by immunofluorescence double-labeling of paraffin-embedded TG and SPG tissue. To localize CYP2J-and sEH-immunoreactivity (IR) in the TG and SPG, thin ganglia slices (6 µm) were deparafinized, heated in 0.5 mmol/L sodium citrate buffer (pH = 6.0) for antigen retrieval, and blocked with 3% normal donkey serum, 0.1% Triton X-100, and 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 30 min at room temperature. Sections were incubated at 4°C overnight with one or two of the following primary antibodies: rabbit anti CYP2J2 rec (1:100) (30), rabbit anti-sEH (1:100, Santa Cruz), mouse anti-NeuN (1:1000), rabbit anti-Fluorogold (1:5000), sheep anti-neuronal nitric oxide synthase (nNOS, 1:1000), guinea pig anti-vasoactive intestinal peptide (VIP, 1:1000), guinea pig anti-substance P (SP, 1:000; Millipore); goat anti-calcitonin gene-related peptide (CGRP, 1:1000; Serotec). Secondary detection was conducted with donkey anti-rabbit Alexa Fluor-488, donkey anti-mouse Alexa Fluor-594, donkey anti-sheep Alexa Fluor-594, goat anti-guinea pig Alexa Fluor-594, and donkey anti-goat Alexa Fluor-594 (1:800, Invitrogen) incubated at room temperature for 1 hr.
Sections were mounted with ProLong Antifade Gold with DAPI (Invitrogen), coverslipped and observed by conventional fluorescence microscopy (Leica). Co-localization was quantified by counting positively-labeled cells from six bilateral TG and SPG slices from each of two separate rats.
In cases where co-labeling was employed between two primary antibodies from rabbit hosts, labeling was conducted sequentially: the first primary antibody was incubated as above overnight at 4°C, this primary incubated with an excess of monovalent goat anti-rabbit Fab fragments (1:10, Jackson Immunoresearch) for 1 hr at room temperature, secondary detection of the Fab fragment conducted with donkey anti-goat Alexa Fluor-594 secondary (1:800, Invitrogen) for 1 hr at room temperature. The second primary antibody was then incubated for 1 hr at room temperature, followed by secondary detection with donkey anti-rabbit Alexa Fluor-488 antibody (1:800, Invitrogen).
Negative controls included both the omission of primary antibodies (n = 1), and the preabsorption of the rabbit anti-CYP2J2 rec and rabbit anti-sEH antibodies with a molar excess of recombinant human CYP2J2 and recombinant human sEH protein, respectively (n = 1). In addition, to confirm the specificity of the observed labeling, slices were incubated with separate anti-CYP2J and anti-sEH antibodies raised against distinct antigens. These included two raised against synthetic peptides from the mouse CYP2J6 (QMEQNIMNRPLSVMQ, anti-CYP2J6pep1, n = 1) and CYP2J9 (GQARQPNLADRD, anti-CYP2J9pep2, n = 1) isoforms that cross-react with rat CYP2J4 and CYP2J3 isoforms, respectively (31) . Further, an anti-sEH antibody raised against recombinant human sEH (n = 1) (6) and another raised against a distinct peptide sequence of human sEH (DMKGYGESSAPPEIE, Cayman, n = 1) were employed.
Determining the origin of fibers projecting to the cerebral circulation
Retrograde Fluorogold nerve tracing was employed to confirm that nerve fibers originating in the TG or SPG project to the cerebral circulation. Animals were anesthetized with 5% isofluorane and placed in a stereotaxic frame. An incision was made in the midline of the scalp and the skull was exposed. A small burr hole 5 mm in diameter was drilled lateral of the saggital suture in the area of the middle cerebral artery, care being taken to leave the dura intact. The dura was incised with a corneal scalpel over the middle cerebral artery and 3 µl of 2% Fluorogold was injected into the sub-dural space with a Hamilton syringe. Following injection, the syringe was left in place for 10 min to prevent spillage of the tracer from the sub-dural space. Sterile gel foam was placed over the burr hole and the scalp was sutured. Animals were survived for 8 days post-injection after which they sacrificed. Perfusion fixation, dissection, processing of tissue was as described above (n = 4 injected animals; 2 negative control, not injected).
Determination of the role of EETs in neurogenic vasodilation in the cerebral circulation
To define the role of EETs in the regulation of the cerebral surface vasculature by perivascular vasodilator nerves, we utilized as a model of neurogenic vasodilation the electrical stimulation of efferent nerve fibers entering the ethmoidal foramen as described by Ayajiki et al. (5) . Briefly, the cerebral surface vasculature was exposed using an open cranial window over the MCA territory of the parietal cortex. Animals were anesthetized with α-chloralose and urethane (50 and 500 mg/kg ip, respectively). The femoral artery and vein were cannulated for the measurement of blood pressure, blood gas values, and the delivery of drugs. Animals were tracheotomized, paralyzed with D-tubocurarine (1 mg/kg) and mechanically ventilated to control arterial blood gas values. The animal's head was fixed in a stereotaxic frame, the skull over the left parietal cortex in the MCA territory was exposed, a craniotomy performed and the dura incised and reflected to provide direct access to the cortical surface vasculature. 
Chemical stimulation of oral trigeminal fibers
A second, more 'physiological' model of neurogenic cerebrovasodilation was evoked through stimulation of oral trigeminal nociceptor fibers as previously described by Gottselig and Messlinger (12) . Cumulative doses of the transient receptor potential vanilloid-1 (TRPV1) agonist capsaicin (300 µl, 10 µmol/L -1 mmol/L) were instilled orally at 10 min intervals, the resulting cortical hyperemia was measured by LDF. To determine the role of EETs signaling in the neurogenic regulation of the cortical vasculature, pharmacological inhibition of portions of the EETs signaling system was employed. In each case, capsaicin dose-response trials were repeated within the same animal, both in the absence and presence of the pharmacological agent. In order to control for sensitization or desensitization of the capsaicin-evoked hyperemic response, half of the trials from each group began with the vehicle treatment arm followed by the drug treatment arm. In the other half, the order was reversed. The two treatment arms were separated by a 1 hr period during which the mouth was liberally irrigated with saline.
Additionally, in a separate group of animals the capsaicin dose-response trials were repeated with the same 1 hr period between arms in order to detect any measurable sensitization or desensitization of this response (n = 4). 
Optical Microangiography
To confirm that the cortical hyperemic response to oral capsaicin administration was in fact the result of cerebral vasodilation, rather than an associated elevation in perfusion pressure, in a limited study (n = 1) we employed a novel optical coherence tomography (OCT)-based imaging technique termed optical microangiography (OMAG) (28, 29) which is capable of resolving 3D distribution of dynamic blood perfusion at the capillary level in vivo. Briefly, the cortex was illuminated at 1310 nm, the resulting backscattered and reference light being detected to produce spectral interferograms within the OMAG system. Volumetric imaging data was collected by scanning the probe beam through a 1000 x 500 x 512 voxel cube, representing 2.5 x 2.5 x 2 mm 3 (x-y-z) of tissue. For high temporal resolution scans, continuous x-z plane scans were performed at a selected segment of the MCA. Imaging of the left MCA was conducted through a thinned skull. Capsaicin (10 μmol/L) was administered orally as above and the resulting hyperemic response was imaged through a thinned skull, including changes in MCA diameter, MCA blood velocity, and MCA volume rate (flow).
Chemicals
Recombinant human CYP2J2 was synthesized as previously described (30 
Results

CYP2J is specifically expressed in TG and SPG neuronal tissue
We sought to determine which CYP EPOX isoforms are present in the TG and SPG, which house the cell bodies of sensory and parasympathetic fibers that innervate the cerebral surface vasculature (13) . An RT-PCR screen using primers against 8 known rat CYP EPOX isoforms in addition to sEH ( 
CYP2J and sEH proteins are present in TG neurons
We conducted immunofluorescence double-labeling of TG slices with antibodies raised against recombinant human CYP2J2 (which cross-reacts with rat CYP2J3 and CYP2J4 (30) ) and sEH to determine the cell type-specific expression of these proteins in the TG. CYP2J2-IR was When primary antibodies were omitted from the double labeling protocol, no labeling of the TG was observed ( Figure 2L ). Likewise, when the anti-CYP2J2 rec and anti-sEH antibodies were preabsorbed with a molar excess of recombinant human CYP2J2 or sEH, no CYP2J2-or sEH-IR was observed within the TG (Figure 2D, H) . To further confirm the specificity of the anti-CYP2J2 rec antibody, TG slices were labeled with two additional antibodies against distinct CYP2J antigens: one against a polypeptide sequence of mouse CYP2J6 that cross-reacts with rat CYP2J4, and another against a polypeptide sequence of mouse CYP2J9 that cross-reacts with rat CYP2J3 (31) . Both of these antibodies displayed similar labeling patters to the anti-CYP2J2 rec antibody (data not shown), although minor differences in cellular and sub-cellular distribution of CYP2J6-and CYP2J9-IR were observed. To confirm the specificity of the antisEH antibody, labeling of TG slices was carried out with two additional anti-sEH antibodies raised against distinct antigens. Labeling with a rabbit polyclonal against recombinant human sEH (6) or a rabbit polyclonal against a distinct polypeptide sequence of human sEH (Cayman Chemical) resulted in immunoreactivity very similar to that of the Santa Cruz antibody (data not shown). Based upon these findings, we conclude that the CYP2J2-IR and sEH-IR observed in TG neurons was specific.
CYP2J and sEH proteins are present in SPG neurons
The expression of CYP2J and sEH was examined in the parasympathetic SPG by immunofluorescence double labeling. As in the TG, probing the SPG with the anti-CYP2J2 rec antibody labeled primarily cells of neuronal morphology ( Figure 4A ). Co-labeling with the neuronal marker NeuN revealed that virtually all CYP2J2-IR (97%) was restricted to neuronal cell bodies while most neurons (91%) were CYP2J2-IR (Figure 4B -C, G). Co-labeling with antibodies against neuronal nitric oxide synthase (nNOS) or VIP revealed that most (82%)
CYP2J2-IR cells were also nNOS-IR ( Figures 3E, 4G ), whereas only a portion of them (25%) appeared to express the neuropeptide VIP ( Figures 3F, 4G ).
Immunofluorescence These data in total argue that both the EETs-synthetic CYP2J (likely both CYP2J3 and CYP2J4 isoforms) and EETs-regulatory sEH proteins are present in neurons of the sensory TG and the parasympathetic SPG.
Neurons innervating the MCA originate in the TG and SPG
Eight days following the subdural injection of the retrograde nerve tracer Fluorogold around the left MCA, Fluorogold-immunoreactivity was detectible both in the TG ( Figure 5A ) and the SPG ( Figure 5B ). Labeling was generally present in the ipsilateral ganglia, however a small number of labeled neurons were observed in contralateral TG. These data confirm that TG and SPG neurons project to the cerebral vasculature, including the MCA.
EETs signaling mediates the regulation of CBF by extrinsic perivascular vasodilator nerves
No treatment (excepting transient hypercapnia) had any significant effect upon mean arterial blood pressure, blood gas values, or the cerebrovascular reactivity to mild hypercapnic ventilation (Table 1) . To test this hypothesis, we identified neuron-specific expression of EPOX and sEH in both the TG and SPG. Such neuronal expression of EPOX and sEH is in agreement with previous studies describing neuronal localization of CYP EPOX and sEH in brain (23, 35) . Furthermore, our finding that CYP2J is expressed in peripheral neurons is consistent with a previous study demonstrating CYP2J expression in autonomic ganglia in human and rat gut (32) . Despite these previous reports of neuronal EPOX and sEH expression, the present study is the first to propose and provide evidence for a functional role of neurogenic EETs, specifically in the regulation of vasomotor tone.
To determine if EETs play a functional role in the neurogenic control of CBF, we stimulated vasodilation using two methods. The first method entailed direct electrical stimulation of efferent nerve fibers innervating the MCA (5), whereas the second involved chemical stimulation of oral nociceptors with the TRPV1 agonist capsaicin as described by Gottselig and Messlinger (12) .
This latter method involves the activation of a neuronal reflex pathway including the trigeminal ganglia, the trigeminal and superior salivary nuclei in the brainstem, and the recruitment of efferent parasympathetic fibers from the SPG ( Figure 7A ). While this method involves the indirect stimulation of parasympathetic vasodilator fibers, it may be considered more 'physiological' than direct nerve stimulation. To confirm that chemical stimulation-evoked dilation is specifically mediated through nerve activation, we demonstrated that lesion of the ethmoidal nerve, which is comprised of trigeminal afferents and efferent parasympathetic SPG fibers innervating the anterior circle of Willis, abolished the CBF response to oral capsaicin administration. We further confirmed that the hyperemic response to oral nociceptor stimulation was attributable to cererbrovasodilation rather than any effect of capsaicin administration on perfusion pressure and blood velocity.
We found that 14,15-EEZE alone slightly reduced basal CBF, suggesting that EETs signaling contributes to the maintenance of resting CBF. Such a finding is in agreement with a previous study in rats demonstrating that inhibition of P450 enzymes with miconazole reduced resting CBF (1). It is inconsistent with other recent findings in which 14,15-EEZE had no discernible effect on resting CBF (25) . These disparate responses, in light of the mild effects of 14,15-EEZE on resting CBF in the present study, suggest that the contribution of EETs signaling to resting CBF may be small in magnitude and sensitive to differences in experimental methodology.
Within both models of neurogenic vasodilation, pre-treatment of the cortical surface vasculature with the putative EETs antagonist 14,15-EEZE markedly attenuated the hyperemic response to chemical or electrical stimulation. Because the CBF response to transient hypercapnia was not altered by 14,15-EEZE, it is unlikely that the small shift in basal vascular tone or a non-specific effect on vascular reactivity accounts for the ability of 14,15-EEZE to inhibit neurogenic hyperemia. These findings suggest that EETs signaling participates in the regulation of CBF by extrinsic perivascular vasodilator nerves.
In contrast to our results with the putative EETs antagonist 14,15-EEZE, administration of the CYP EPOX inhibitor MS-PPOH to the cortical surface did not alter CBF responses to oral trigeminal fiber stimulation. This suggests that de novo synthesis of EETs is not required for the present neurogenic vasodilation and may reflect the existence of a latent membrane phospholipid-bound pool of EETs not depleted within the 45 min treatment window. Such a releasable pool of EETs has been described in vascular endothelium (27) and brain astrocytes (26) . Interestingly, although we report robust CYP2J immunoreactivity in TG and SPG soma, in unpublished work we have been unable to detect CYP2J-IR in perivascular neurons surrounding whole-mount cerebral surface arteries. One explanation for these findings is that in perivascular nerves, EETs may be synthesized centrally while release of these vasoactive compounds may occur peripherally from a latent membrane-bound pool.
We have proposed that the present findings support the hypothesis that vasodilator EETs represent a novel nerve-derived relaxing factor in the cerebral circulation. One limitation to the present study is that the actual release of EETs from cerebral extrinsic perivascular nerve fibers was not measured in response to stimulation. Within the present in vivo context, such measurement would be exceedingly difficult, as methods for EETs detection (such as liquid chromatography tandem mass spectroscopy, LC-MS-MS) have limited sensitivity and do not allow for measurement in local microenvironments such as this neuro-vascular junction.
It is important to note that the cellular mechanisms underpinning regulation of cerebral arteries by parasympathetic and sensory perivascular fibers have been studied in detail and the vasomotor actions of these nerves have been largely attributed to such factors as nitric oxide and the neuropeptides VIP and CGRP (13) . In the study characterizing the CBF response to oral capsaicin administration, the hyperemic response to capsaicin was abolished by the administration of a VIP receptor antagonist to the dural surface (12) . In other studies investigating CBF responses to electrical stimulation of parasympathetic and sensory perivascular fibers, major contributions have been reported for nitric oxide and CGRP (5, 7, 15) .
Given the pronounced effect of 14,15-EEZE upon neurogenic hyperemia reported in the present study, it is likely that the EETs signaling pathway interacts in some manner with these other vasomotor pathways ( Figure 9 ). In one potential mode of interaction, EETs may be released from nerves in response to activation, acting in an additive manner with other neurotransmitters to regulate vascular tone ( Figure 9A ). Similarly, they may act to modulate the action of these neurotransmitters upon the vasculature. In unpublished work, we observed that 100 nmol/L 14,15-EET did not alter the EC 50 or maximal effect of exogenous VIP or CGRP administered directly to the cortical surface. This suggests that EETs do not act to potentiate the actions of these known mediators of neurogenic hyperemia.
A second possibility is that neurogenic EETs are not released per se, but rather act intracellularly to regulate release of other neurotransmitters such as VIP or CGRP ( Figure 9B ).
Such a role was recently observed for prostaglandin E2 in the modulation of nitric oxide release from sphenopalatine ganglia neurons (17) and for cannabidiol in the modulation of CGRP release from dorsal root ganglia neurons (22) . A third possibility is that one or more releasable 
